Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update

Rhea-AI Summary

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its fourth quarter and full year 2020 financial results on March 11, 2021, post-market. A webcast will follow at 2:00 p.m. PT for management to discuss the results and provide a business update. Oncternal is focused on developing novel oncology therapies addressing unmet medical needs, with ongoing clinical studies for cirmtuzumab and TK216. The company's primary aim is to tap into promising biological pathways involved in cancer progression.

Positive

• Ongoing Phase 1/2 clinical trials for cirmtuzumab and TK216 indicate active product development.
• Focus on innovative therapies targeting unmet medical needs could enhance long-term market positioning.

Negative

• None.

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company’s financial results and provide a comprehensive business update.

The live webcast of the call will be available online via a link from the investor relations page of the Company’s website at www.oncternal.com, and the call will be archived there for at least 30 days. 

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

Oncternal Contacts:

Company Contact
Richard Vincent
858-434-1113
rvincent@oncternal.com 

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

Source: Oncternal Therapeutics, Inc.

FAQ

When will Oncternal report its financial results?

Oncternal will report its fourth quarter and full year 2020 financial results after the market closes on March 11, 2021.

What is the purpose of Oncternal's upcoming webcast?

The webcast will discuss Oncternal's financial results and provide a comprehensive business update.

What is Oncternal's focus in drug development?

Oncternal focuses on developing novel therapies targeting critical unmet medical needs in oncology.

What clinical trials are currently underway for Oncternal?

Oncternal is conducting Phase 1/2 trials for cirmtuzumab and TK216 to treat various forms of cancer.

Where can I access Oncternal's financial results?

The financial results will be available on Oncternal's investor relations page after the report is released.